Clinical Trial Update: Multiple Myeloma is a Hematologic Malignancy Characterized by the Accumulation of Malignant Plasma Cells in the Bone Marrow. Despite Advances in Treatment, Many Patients Experience Disease Relapse. Bispecific Antibodies Offer an Innovative Therapeutic Approach, But Approximately 30%-40% of Patients

View source ↗

Summary

This clinical trial update notes that multiple myeloma remains a relapse-prone hematologic malignancy and highlights bispecific antibodies as an innovative ther…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Snippet

Sponsor: Tel-Aviv Sourasky Medical Center | Conditions: Multiple Myeloma (MM) | Status: NOT_YET_RECRUITING